Eslicarbazepine acetate 400 MG Oral Tablet — RxCUI 1482515
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Eslicarbazepine: what it is, how it’s used, side effects, and interactions.
- Sure. Eslicarbazepine acetate (brand name Aptiom) is specifically approved to treat partial-onset seizures — that's when a seizure starts in just one area of the brain rather than...
- What exactly is this medicine for? My doctor said it's for seizures — can you tell me more?
- Good news — food doesn't affect how this medicine works, so you can take it with or without a meal, whichever is easier for you. It's taken just once a day, which most people find...
- Can I take this pill with food, or does it have to be on an empty stomach?
🕸️ Concept Web — How Eslicarbazepine acetate 400 MG Oral Tablet Connects
RxCUI 1482515 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 2
The active substance itself — no strength, form, or brand attached yet.
-
Eslicarbazepine
1482502IN -
Eslicarbazepine acetate
1482501PIN
-
Eslicarbazepine
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Aptiom
1482508BN
-
Aptiom
-
Dose forms 13
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Eslicarbazepine Oral Tablet
1482506SCDF -
Eslicarbazepine acetate Oral Tablet
2647024SCDFP -
Eslicarbazepine Oral Product
1482504SCDG -
Eslicarbazepine Pill
1482505SCDG -
Eslicarbazepine acetate Oral Product
2662353SCDGP -
Eslicarbazepine acetate Pill
2660612SCDGP -
Eslicarbazepine Oral Tablet [Aptiom]
1482510SBDF -
Eslicarbazepine acetate Oral Tablet [Aptiom]
2654181SBDFP - +5 more in this family
-
Eslicarbazepine Oral Tablet
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Eslicarbazepine acetate 400 MG
1482514SCDC -
Eslicarbazepine acetate 400 MG Oral Tablet [Aptiom]
1482517SBD -
Eslicarbazepine acetate 400 MG [Aptiom]
1482516SBDC
-
Eslicarbazepine acetate 400 MG
-
Packs 2
Fixed collections of drugs packaged and sold together, like dose packs.
🔀 Generic ⇄ Brand Crosswalk
Generic (Clinical) Concepts
-
{7 (eslicarbazepine acetate 400 MG Oral Tablet) / 7 (eslicarbazepine acetate 800 MG Oral Tablet) } Pack
GPCK · 1491642 -
Eslicarbazepine acetate 400 MG
SCDC · 1482514 -
Eslicarbazepine Oral Tablet
SCDF · 1482506 -
Eslicarbazepine acetate Oral Tablet
SCDFP · 2647024 -
Eslicarbazepine Oral Product
SCDG · 1482504 -
Eslicarbazepine Pill
SCDG · 1482505 -
Eslicarbazepine acetate Oral Product
SCDGP · 2662353 -
Eslicarbazepine acetate Pill
SCDGP · 2660612
Brand-Name Concepts
-
Eslicarbazepine acetate 400 MG Oral Tablet [Aptiom]
SBD · 1482517 -
{7 (eslicarbazepine acetate 400 MG Oral Tablet [Aptiom]) / 7 (eslicarbazepine acetate 800 MG Oral Tablet [Aptiom]) } Pack [Aptiom Titration Sample Pack]
BPCK · 1491643 -
Eslicarbazepine acetate 400 MG [Aptiom]
SBDC · 1482516 -
Eslicarbazepine Oral Tablet [Aptiom]
SBDF · 1482510 -
Eslicarbazepine acetate Oral Tablet [Aptiom]
SBDFP · 2654181 -
Aptiom Oral Product
SBDG · 1482511 -
Aptiom Pill
SBDG · 1482512 -
Aptiom
BN · 1482508
📦 FDA Products & Package NDCs
37 products · 70 package NDCs
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 60505-4660-09 | 90 TABLET in 1 BOTTLE (60505-4660-9) | Eslicarbazepine Acetate | Apotex Corp. | 2025-05-06 |
| 60505-4661-03 | 30 TABLET in 1 BOTTLE (60505-4661-3) | Eslicarbazepine Acetate | Apotex Corp. | 2025-05-06 |
| 60505-4661-09 | 90 TABLET in 1 BOTTLE (60505-4661-9) | Eslicarbazepine Acetate | Apotex Corp. | 2025-05-06 |
| 63402-0202-28 | 4 BLISTER PACK in 1 CARTON (63402-202-28) / 7 TABLET in 1 B... | Aptiom | Sumitomo Pharma America, Inc. | 2017-09-13 |
| 63402-0202-30 | 30 TABLET in 1 BOTTLE (63402-202-30) | Aptiom | Sumitomo Pharma America, Inc. | 2014-04-07 |
| 63402-0204-28 | 4 BLISTER PACK in 1 CARTON (63402-204-28) / 7 TABLET in 1 B... | Aptiom | Sumitomo Pharma America, Inc. | 2014-04-07 |
| 63402-0204-30 | 30 TABLET in 1 BOTTLE (63402-204-30) | Aptiom | Sumitomo Pharma America, Inc. | 2014-04-07 |
| 63402-0206-28 | 4 BLISTER PACK in 1 CARTON (63402-206-28) / 7 TABLET in 1 B... | Aptiom | Sumitomo Pharma America, Inc. | 2014-04-07 |
| 63402-0206-60 | 60 TABLET in 1 BOTTLE (63402-206-60) | Aptiom | Sumitomo Pharma America, Inc. | 2014-04-07 |
| 63402-0208-28 | 4 BLISTER PACK in 1 CARTON (63402-208-28) / 7 TABLET in 1 B... | Aptiom | Sumitomo Pharma America, Inc. | 2014-04-07 |
| 63402-0208-30 | 30 TABLET in 1 BOTTLE (63402-208-30) | Aptiom | Sumitomo Pharma America, Inc. | 2014-04-07 |
| 63402-0248-56 | 4 BLISTER PACK in 1 CARTON (63402-248-56) / 1 KIT in 1 BLIS... | Aptiom | Sumitomo Pharma America, Inc. | 2014-04-07 |
| 67877-0585-30 | 30 TABLET in 1 BOTTLE (67877-585-30) | Eslicarbazepine Acetate | Ascend Laboratories, LLC | 2025-05-06 |
| 67877-0586-30 | 30 TABLET in 1 BOTTLE (67877-586-30) | Eslicarbazepine Acetate | Ascend Laboratories, LLC | 2025-05-06 |
| 67877-0587-60 | 60 TABLET in 1 BOTTLE (67877-587-60) | Eslicarbazepine Acetate | Ascend Laboratories, LLC | 2025-05-06 |
| 67877-0588-30 | 30 TABLET in 1 BOTTLE (67877-588-30) | Eslicarbazepine Acetate | Ascend Laboratories, LLC | 2025-05-06 |
| 68180-0290-06 | 30 TABLET in 1 BOTTLE (68180-290-06) | Eslicarbazepine Acetate | Lupin Pharmaceuticals, Inc. | 2025-05-06 |
| 68180-0291-06 | 30 TABLET in 1 BOTTLE (68180-291-06) | Eslicarbazepine Acetate | Lupin Pharmaceuticals, Inc. | 2025-05-06 |
| 68180-0292-07 | 60 TABLET in 1 BOTTLE (68180-292-07) | Eslicarbazepine Acetate | Lupin Pharmaceuticals, Inc. | 2025-05-06 |
| 68180-0293-06 | 30 TABLET in 1 BOTTLE (68180-293-06) | Eslicarbazepine Acetate | Lupin Pharmaceuticals, Inc. | 2025-05-06 |
🗃️ Sources & Limits
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.